SCHEMBL6299041

SCHEMBL6299041

O=C1OC(Oc2ccc(F)cc2)(C(=O)OCc2ccccc2)c2ccccc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
MAPT P10636 1/20 0.39
CTRB1 P17538 1/20 0.37
PPARG P37231 1/20 0.36
PPARA Q07869 1/20 0.36
DDB1 Q16531 1/20 0.36
CRBN Q96SW2 1/20 0.36
MAOB P27338 2/20 0.36
MGLL Q99685 1/20 0.36
KMT2A Q03164 1/20 0.36
FABP7 O15540 1/20 0.36
FABP5 Q01469 1/20 0.36
NR4A2 P43354 1/20 0.35
CDC25B P30305 1/20 0.35
PDK2 Q15119 1/20 0.35
MAOA P21397 1/20 0.35
FFAR1 O14842 1/20 0.35
FFAR4 Q5NUL3 1/20 0.35
ALDH1A1 P00352 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4261355 0.83 NPSR1 (0.47) GAANPSR1MAPTKMT2AALDH1A1
SCHEMBL21160844 0.78 CTRB1 (0.45) GAANPSR1MAPTCTRB1DDB1
SCHEMBL6303522 0.75 DDB1 (0.42) GAANPSR1MAPTCTRB1DDB1
SCHEMBL6297178 0.74 DDB1 (0.46) GAANPSR1MAPTCTRB1DDB1
SCHEMBL4607575 0.73 ALDH1A1 (0.45) GAANPSR1MAPTCTRB1DDB1
SCHEMBL18663247 0.67 ALDH1A1 (0.50) NPSR1MAPTCTRB1DDB1CRBN
SCHEMBL6297349 0.64 DDB1 (0.44) DDB1CRBNKMT2AFABP7FABP5
SCHEMBL9407475 0.63 LMNA (0.50) MAPTMAOBMGLLKMT2AFABP7
SCHEMBL8313978 0.63 SIGMAR1 (0.60) NPSR1KMT2A
SCHEMBL10550851 0.63 DDB1 (0.48) DDB1CRBNKMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050143453-A1 Selective preventing and therapeutic agents for progressive lesion after organic damage ISHIBASHI MICHIO (JP) 2005-06-30 US disclosed
US-6878745-B2 Selective preventives/remedies for progressive lesions after organ damage Ishibashi, Michio (JP) 2005-04-12 US disclosed
US-20030181506-A1 Selective preventives/remedies for progressive lesions after organ damage ISHIBASHI, MICHIO (JP) 2003-09-25 US disclosed
EP-1277747-A1 SELECTIVE PREVENTIVES/REMEDIES FOR PROGRESSIVE LESIONS AFTER ORGAN DAMAGE Ishibashi, Michio (JP) 2003-01-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181506-A1 Selective preventives/remedies for progressive lesions after organ damage CCL11, CD68, CCL2 GAA 868/4885NPSR1 1602/4885MAPT 4567/4885
US-20050143453-A1 Selective preventing and therapeutic agents for progressive lesion after organic damage CD68, MSR1, CCL2 GAA 708/4885NPSR1 2219/4885MAPT 4454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.